SCHEMBL6469935

SCHEMBL6469935

CC(=O)c1cccc(Br)c1C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
F2R P25116 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PRNP P04156 1/20 0.38
BRPF1 P55201 1/20 0.38
LMNA P02545 1/20 0.38
AHR P35869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11089840 0.84 PRNP (0.47) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL4443208 0.83 ALDH1A1 (0.40) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL211283 0.83 TSHR (0.52) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL4415281 0.83 ALDH1A1 (0.36) ALDH1A1HPGDHSD17B10NPC1RAB9A
SCHEMBL29621571 0.83 TSHR (0.52) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL16962049 0.82 ALDH1A1 (0.39) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL3710686 0.81 ALDH1A1 (0.42) ALDH1A1HPGDHSD17B10KMT2AMEN1
Hydrochloric Acid SCHEMBL15351222 0.81 TSHR (0.50) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL16357915 0.81 ALDH1A1 (0.39) ALDH1A1HPGDHSD17B10KMT2AMEN1
SCHEMBL1363612 0.81 METAP2 (0.45) ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005110955-A1 SUBSTITUTED ACETOPHENOME AS MS REAGENTS GE HEALTHCARE BIO-SCIENCES AB (SE) 2005-11-24 WO claimed
US-20250382290-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-12-18 US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
EP-4543450-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-30 EP disclosed
WO-2025070947-A1 NOVEL PHTHALAZINE DERIVATIVE COMPOUND AS SOS1 INHIBITOR, AND USE THEREOF 한미약품 주식회사 2025-04-03 WO disclosed
CN-119546304-A Salts of SOS1 inhibitors 米拉蒂治疗公司 2025-02-28 CN disclosed
US-20250059182-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS, INC 2025-02-20 US disclosed
CN-119462626-A SOS1 inhibitors 米拉蒂治疗股份有限公司 2025-02-18 CN disclosed
US-20250042857-A1 SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure HAIHE BIOPHARMA CO., LTD. (CN) 2025-02-06 US disclosed
WO-2013151923-A1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-10 WO disclosed
WO-2013151923-A1 PYRIMIDINONE CARBOXAMIDES AS INHIBITORS OF ENDOTHELIAL LIPASE BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-10 WO disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
WO-2010131922-A2 AMIDE COMPOUND, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-11-18 WO disclosed
WO-2005110955-A1 SUBSTITUTED ACETOPHENOME AS MS REAGENTS GE HEALTHCARE BIO-SCIENCES AB (SE) 2005-11-24 WO disclosed
CN-1102586-C Gamma-butenolide containing aryl substituent at beta position and its solid-phase synthesis process SHANGHAI INST ORGANIC CHEM (CN) 2003-03-05 CN disclosed
CN-1273245-A Gamma-butenolide containing aryl substituent at beta position and its solid-phase synthesis process SHANGHAI INST ORGANIC CHEM (CN) 2000-11-15 CN disclosed
US-4064132-A ANTIINFLAMMATORY AGENTS JANSSEN PHARMACEUTICA N.V. (BE) 1977-12-20 US disclosed
US-4060528-A ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-11-29 US disclosed
US-4035376-A ESTERS, AMIDES, HYDROXAMIC ACIDS, ANTIINFLAMMATORY JANSSEN PHARMACEUTICA N.V. (BE) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042857-A1 SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure SOS1, MEN1, BRCA1 ALDH1A1 2225/4885HPGD 3204/4885HSD17B10 3484/4885
US-20250382290-A1 SALTS OF SOS1 INHIBITORS SOS1, SOS2, SOST ALDH1A1 3158/4885HPGD 3957/4885HSD17B10 3340/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 ALDH1A1 3260/4885HPGD 3255/4885HSD17B10 3669/4885
US-20250059182-A1 SOS1 INHIBITORS SOS1, SOS2, SOST ALDH1A1 3367/4885HPGD 3484/4885HSD17B10 3792/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 ALDH1A1 3260/4885HPGD 3255/4885HSD17B10 3669/4885
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 ALDH1A1 538/4885HPGD 3711/4885HSD17B10 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.